Asitri Dashboard

Search Clinical Trials

The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.

Saved Searches

Choose Search
Basic Search
Targeted Search

Clinical Trials Search Results

Search History:
Count: 285
Selected: 0
NCT IDTitle
NCT01614470Study of Ivacaftor in Subjects With Cystic Fibrosis (CF) Who Have a Non-G551D CF Transmembrane Conductance Regulator (CFTR) Gating Mutation
NCT06506773Natural History Study of Exocrine Pancreatic Function in Infants With Cystic Fibrosis (CF)
NCT00953706Study of Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Homozygous for the F508del-CFTR Mutation
NCT05111145A Study Evaluating the Safety of Elexacaftor/Tezacaftor/Ivacaftor in Participants With Cystic Fibrosis (CF)
NCT04977336A Study Evaluating Efficacy and Safety of VX-548 for Acute Pain After a Bunionectomy
NCT03338595Longitudinal Assessment of Exercise Capacity and Vascular Function in Patients With CF
NCT02953314A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of VX-661/Ivacaftor in Pediatric Subjects With Cystic Fibrosis (CF)
NCT03655678A Safety and Efficacy Study Evaluating CTX001 in Participants With Transfusion-Dependent β-Thalassemia
NCT04474197Evaluation of the Efficacy and Safety of VX-864 in Subjects With the PiZZ Genotype
NCT05660538Evaluation of Efficacy and Safety of VX-548 for Painful Diabetic Peripheral Neuropathy (DPN)
NCT00909727Study of Ivacaftor in Cystic Fibrosis Subjects Aged 6 to 11 Years With the G551D Mutation
NCT05951205Evaluation of Efficacy and Safety of a Single Dose of Exa-cel in Participants With Severe Sickle Cell Disease, βS/ βC Genotype
NCT06861413A Phase 1 Study to Evaluate the Relative Bioavailability of a VX-828 Tablet Formulation
NCT07654296Assessing Suzetrigine for Pain Reduction Following Ureteroscopic Surgery
NCT00262483Phase 2 Study of VX-950, Pegasys and Copegus in Hepatitis C
NCT00003847VX-710, Doxorubicin, and Vincristine for the Treatment of Patients With Recurrent Small Cell Lung Cancer
NCT00623649Safety,Tolerability and Pharmacokinetics of Multiple Ascending Doses of VCH 916 in Subjects With Chronic Hep C Infection
NCT03768089Study of VX-121 in Healthy Subjects and in Subjects With Cystic Fibrosis
NCT01886209Phase 1 PK Interaction Study Between VX-509 and Prednisone or Methylprednisolone in Healthy Male Subjects
NCT03525444A Phase 3 Study of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)
NCT00389298A Proof-of-concept Study of VCH-759 for the Treatment of Hepatitis C-infection.
NCT05455502A Study to Evaluate the Relative Bioavailability and Food Effect of a New Tablet Formulation of VX-548
NCT01768663A Phase 1 Study to Examine the Drug-Drug Interaction of Ciprofloxacin, Itraconazole, and Rifampin on the Combination of Lumacaftor With Ivacaftor in Healthy Adult Subjects
NCT04537793Evaluation of ELX/TEZ/IVA in Cystic Fibrosis (CF) Subjects 2 Through 5 Years
NCT05076149A Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Who Are Homozygous for F508del, Heterozygous for F508del and a Gating (F/G) or Residual Function (F/RF) Mutation, or Have At Least 1 Other Triple Combination Responsive (TCR) CFTR Mutation and No F508del Mutation
NCT01208285Study of VX-770 in Subjects With Moderate Hepatic Impairment and in Matched Healthy Subjects
NCT05347394A Phase 1 Dose Escalation Study of Oral VX-708 in Healthy Participants
NCT01080222A Safety and Efficacy Study of the Combination of VX-222 and Telaprevir in Treatment-Naïve Subjects With Genotype 1 Chronic Hepatitis C Virus Infection
NCT07437105Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy Participants
NCT05553366Evaluation of Efficacy and Safety of VX-548 for Acute Pain After a Bunionectomy
NCT00916474Virology Follow up Study in Subjects Previously Treated With Telaprevir
NCT01225211Study of VX-809 Alone and in Combination With VX-770 in Cystic Fibrosis (CF) Patients Homozygous or Heterozygous for the F508del-CFTR Mutation
NCT01381289VX-770 Expanded Access Program
NCT06154447Evaluation of VX-828 in Healthy Participants and in Participants With Cystic Fibrosis
NCT05418712A Microneurography (MNG) Study of VX-150 in Healthy Participants
NCT01790100A Phase 2a, Dose-Ranging Study to Evaluate the Safety, Pharmacokinetics and Efficacy of VX-135 With Ribavirin in Treatment-Naïve Subjects With Chronic Hepatitis C
NCT04058366Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy
NCT00983853Safety and Efficacy of Telaprevir in Combination With Peginterferon Alfa-2a and Ribavirin in Subjects Co-Infected With Hepatitis C Virus (HCV) and HIV
NCT06696443Evaluation of the Long-term Safety and Effectiveness of Suzetrigine (SUZ) in Participants With Painful Diabetic Peripheral Neuropathy (DPN)
NCT06628908Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy
NCT00958152Drug-Drug Interaction Study of VCH-222 and Telaprevir in Healthy Subjects
NCT01863238An Ocular Safety Study of Ivacaftor-Treated Pediatric Patients 11 Years of Age or Younger With Cystic Fibrosis
NCT00621296Safety and Efficacy of MP-424 to Treat Chronic Hepatitis C
NCT02347657A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor
NCT00336479Phase 2 Study of VX-950, Pegasys®, and Copegus® in Hepatitis C
NCT03460990A Study of VX-659 Combination Therapy in CF Subjects Homozygous for F508del (F/F)
NCT05477563Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease
NCT00627926A Phase 3 Study of Telaprevir in Combination With Pegasys® and Copegus® in Treatment-Naive Subjects With Genotype 1 Hepatitis C Virus (HCV)
NCT02951182A Study Evaluating the Safety and Efficacy of VX-440 Combination Therapy in Subjects With Cystic Fibrosis
NCT03150719A Study to Evaluate Safety, Efficacy, and Tolerability of TEZ/IVA in Orkambi® (Lumacaftor/Ivacaftor) -Experienced Subjects With Cystic Fibrosis (CF)